GATA3 haploinsufficiency does not block allergic sensitization or atopic disease - 05/02/16
Doi : 10.1016/j.jaci.2015.06.041
Monica G. Lawrence, MD a, Jennifer W. Leiding, MD b, c, ∗, Jonathan J. Lyons, MD d, ∗, Amy P. Hsu, BS b, Celeste C. Nelson, CRNP d, Nina Jones, RN e, Alan Fitzgerald, RN b, Wade W. Chien, MD f, g, Lisa Workman, BA a, Thomas A. Platts-Mills, MD a, Carmen Brewer, PhD f, Rachel I. Gafni, MD h, Kelly D. Stone, MD, PhD d, Joshua D. Milner, MD d, ‡, Steven M. Holland, MD b, ‡ 
a Asthma and Allergic Diseases Center, University of Virginia Health System, Charlottesville, Va
b Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md
d Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Md
c Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, University of South Florida, St Petersburg, Fla
e Clinical Research Directorate/CMRP, Leidos Biomedical Research, Inc, National Laboratory for Cancer Research, Frederick, Md
f Division of Intramural Research, National Institute on Deafness and Other Communication Disorders, NIH, Bethesda, Md
g Department of Otolaryngology–Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Md
h National Institute of Dental and Craniofacial Research, NIH, Bethesda, Md
| This research was supported in part by the Intramural Research Programs of the National Institute of Allergy and Infectious Diseases, the National Institute on Deafness and Other Communication Disorders, and the National Institute of Dental and Craniofacial Research. N.J. is additionally funded by this statement: This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. |
|
| Disclosure of potential conflict of interest: M. G. Lawrence has received consultancy fees from Baxter as a member of the Advisory Board. J. W. Leiding has received consultancy fees from the Academy for Continued Healthcare Learning; has received research support from the American Academy of Allergy, Asthma & Immunology ARTrust, All Children's Hospital Foundation; and has received lecture fees from Vidara Therapeutics and Immunodeficiency Foundation. T. A. Platts-Mills has received research support from Thermo-Fisher/Phadia. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
Publié par Elsevier Masson SAS.
Vol 137 - N° 2
P. 627 - février 2016 Retour au numéro
Article précédent
- Type 2 innate lymphoid cells in induced sputum from children with severe asthma
- Prasad Nagakumar, Laura Denney, Louise Fleming, Andrew Bush, Clare M. Lloyd, Sejal Saglani
- Ole e 1, Ole e 7, and Ole e 9: Identifying distinct clinical subsets of olive tree–allergic patients
- Enrico Scala, Damiano Abeni, Debora Pomponi, Roberto Paganelli, Maria Locanto, Mauro Giani, Lorenzo Cecchi, Riccardo Asero
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?